Healthcare and Pharmaceuticals - Related News

27/02/2017 - Iona McCall speaks at 11th Annual SMi Parallel Trade Conference for Pharmaceuticals

Iona McCall, Managing Consultant at Europe Economics, spoke about the case against parallel trade at the 11th Annual SMi Parallel Trade Conference for Pharmaceuticals, which took place in London on 6-7 February 2017. 

29/09/2016 - 11th Annual SMi Parallel Trade Conference for Pharmaceuticals

Our founder and Senior Adviser Dermot Glynn will be speaking at the 11th Annual SMi Parallel Trade Conference for Pharmaceuticals, taking place in London on 6-7 February 2017. The discussion will include looking at the impact Brexit and the new EU Falsified Medicine Directive might have on parallel trade.

27/07/2016 - Briefing Paper: Brexit and the Pharmaceutical Industry

In this briefing paper Andrew Lilico, Executive Director, and Kareen El Beyrouty, Senior Consultant at Europe Economics, discuss the key implications of Brexit for the pharmaceutical industry. The discussion focuses on national drug budgets, parallel trade and intellectual property, trade agreements, R&D funding and the free movement of people, access to finance, and regulatory governance. These issues are discussed through the lens of what we view as the most likely outcomes of Brexit and we highlight some of the key questions that the pharmaceutical industry should be thinking through at this time. To purchase the briefing paper, please email enquiries@europe-economics.com.   

20/06/2016 - The case against parallel trade in respect of patented drugs

 An article by Dermot Glynn, Senior Advisor at Europe Economics.

26/02/2016 - Is price transparency always beneficial?  

The current issue of the Competition Law Journal includes an article by Dermot Glynn which distinguishes two types of market: in Type A price transparency improves the competitive process and consumer welfare; in Type B markets however there are good social policy reasons for charging different prices according to ability to pay, and price transparency tends to prevent this. Patented pharmaceuticals are an important example of Type B markets, in which confidentiality contributes to consumer welfare.